The addition of capecitabine to temozolomide demonstrated a benefit in patients with advanced pancreatic neuroendocrine tumors (NETs), according to data presented at the 2022 annual meeting of the American Society of Clinical Oncology (abstract 4004).
The updated final analysis of the phase 2 ECOG-ACRIN E2211 trial showed a significant eight-month improvement in progression-free survival (PFS) with the combination of capecitabine and temozolomide versus temozolomide alone (hazard ratio [HR],
SEPTEMBER 2, 2022